| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 12/26/2002 | US20020197204 Method for producing alpha-alumina formed body |
| 12/26/2002 | US20020195452 Stackable low depth tray |
| 12/25/2002 | CN1387568A Modified ciliary neurotrophic factor, method of making and methods of use thereof |
| 12/25/2002 | CN1387567A Conjugates between peptides and nucleic acid analog, such as PNA, LNA or morpholino |
| 12/25/2002 | CN1387542A Microbicidal additives |
| 12/25/2002 | CN1387505A Compositions contg. hydroxyeicosatetraenoic acid derivs, and methods of use in treating dry eye disorders |
| 12/25/2002 | CN1387503A Hydroxyeicosatetraenoate salts, composition and method of use in treating dry eye disorders |
| 12/25/2002 | CN1387444A Method of treatment using anti-ErbB antibody-maytansinoid conjugates |
| 12/25/2002 | CN1387443A 联合疫苗组合物 Combined vaccine composition |
| 12/25/2002 | CN1387436A Preventive and therapeutic agents for eye diseases |
| 12/25/2002 | CN1387433A Method for administering phosphodiesterase 4 inhibitor |
| 12/25/2002 | CN1387428A Sustained-release drug formulations for implantation |
| 12/25/2002 | CN1386548A Process for preparing transgenic compound particles of alkylated chitosan |
| 12/25/2002 | CN1096869C Sustained release formulation of animal growth hormone and process for preparation thereof |
| 12/25/2002 | CN1096862C Controlled-release dosage form of azithromycin |
| 12/25/2002 | CN1096858C Gepirone dosage form |
| 12/25/2002 | CN1096856C Method for topical treatment of scar tissue and related tissue reaction to trauma |
| 12/25/2002 | CN1096851C Adjuvant for vaccine compsoition |
| 12/25/2002 | CN1096843C Cosmatic and/or dermal composition contg. salicyclic acid |
| 12/24/2002 | US6498945 Free radical generation of water soluble polymer to enhance cytopathogenic efficacy |
| 12/24/2002 | US6498237 Induction of endhotelial procoagulant is inhibited and induction of fibrin deposition is enhanced; cytotoxicity and receptor binding activities unaffected; monoclonal antibody |
| 12/24/2002 | US6498229 Direct synthesis of segmented glycolide copolymers and crystalline materials therefrom |
| 12/24/2002 | US6498191 For treatment of alzheimer's disease, diabetes mellitus, parkinson's disease, neuronal and cardiac ischemia, huntington's disease, stroke |
| 12/24/2002 | US6498152 Use of a farnesyl transferase inhibitor in the manufacture of a medicament for local administration to the vascular wall in the prevention of restenosis |
| 12/24/2002 | US6498148 Immunization-free methods for treating antigen-stimulated inflammation in a mammalian host and shifting the host's antigen immune responsiveness to a Th1 phenotype |
| 12/24/2002 | US6497949 Adhesive blends comprising hydrophilic and hydrophobic pressure sensitive adhesives |
| 12/24/2002 | US6497905 Aqueous solubility pharmaceutical formulations |
| 12/24/2002 | US6497904 Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent |
| 12/24/2002 | US6497903 Hydrolysable hydrogels for controlled release |
| 12/24/2002 | US6497902 Biocompatible adhesive or glue |
| 12/24/2002 | US6497899 Pharmaceutically acceptable steam extruded polymer, and medicament; rapid oral drug delivery or as vaginal or rectal suppositories or for oral delivery of veterinary drugs |
| 12/24/2002 | US6497898 Stability, drug and cosmetic delivery |
| 12/24/2002 | US6497895 Transdermal patch |
| 12/24/2002 | US6497888 Process for limiting the penetration into the skin and/or the keratinous fibres of an active cosmetic and/or pharmaceutical agent |
| 12/24/2002 | US6497887 Delivery system for topical application to skin comprising freeze-dried, partially crosslinked polymeric gel membrane containing hyaluronic acid as disrupting agent, which can be returned to dissolvable gel upon application of wetting agent |
| 12/24/2002 | US6497886 1,3-bis-(N-lactamyl) propane and the pharmaceutical and cosmetic use thereof |
| 12/24/2002 | US6497881 Complex comprising streptavidin-protein a fusion protein having antibody and biotin binding sites, bound antibody specific for cell surface protein, which undergoes endocytosis after binding, bound biotinylated toxin, expressed in cell |
| 12/24/2002 | US6497874 Modified filamentous phage which retains ability to bind and infect helicobacter pylori |
| 12/24/2002 | US6497869 Having a ph of 5.0 to 8.0, and a salt comprising sulfate ions; treatment of shipping fever, bovine mastitis |
| 12/24/2002 | US6497867 Use of copolymers of monoethylenically unsaturated carboxylic acids as solubilizers |
| 12/24/2002 | US6497859 Cooling agents, pharmaceutical compositions having cooling agents and processes for making and using same |
| 12/24/2002 | CA2278802C Ophthalmic compositions including glycerin and propylene glycol |
| 12/24/2002 | CA2222133C Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen |
| 12/24/2002 | CA2081070C Buoyant controlled release powder formulation |
| 12/24/2002 | CA2065462C Radiopharmaceutical bacteriostats |
| 12/22/2002 | CA2391078A1 Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
| 12/19/2002 | WO2002101412A2 Spray freeze-dried compositions |
| 12/19/2002 | WO2002100996A1 Azeotrope-like compositions of tetrafluoroethane pentafluoropropane, methylbutane and water |
| 12/19/2002 | WO2002100901A2 Determination of bone-sialoprotein in bodily fluids for oncological problems |
| 12/19/2002 | WO2002100879A1 Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives |
| 12/19/2002 | WO2002100529A1 Unimolecular polymeric micelles with an ionizable inner core |
| 12/19/2002 | WO2002100506A1 Azeotrope-like compositions of tetrafluoroethane, pentafluoropropane and water |
| 12/19/2002 | WO2002100440A1 Conjugates of polysaccharide polymers of natural origin |
| 12/19/2002 | WO2002100439A1 Water-soluble stabilized self-assembled polyelectrolytes |
| 12/19/2002 | WO2002100437A2 Ophthalmic compositions comprising hyaluronic acid |
| 12/19/2002 | WO2002100436A2 Ophthalmic once-a-day composition |
| 12/19/2002 | WO2002100435A1 Compositions and methods for enhancing nucleic acid transfer into cells |
| 12/19/2002 | WO2002100425A1 Aggregate composition for sustained-release preparation, process for producing the same, and sustained-release preparation containing the same |
| 12/19/2002 | WO2002100422A1 Pharmaceutical formulation consisting of a plant dry extract with a calcium coating |
| 12/19/2002 | WO2002100418A1 Exothermic formulations for the treatment of ectoparasites |
| 12/19/2002 | WO2002100412A2 Stabilized dispersion of phytosterol in oil |
| 12/19/2002 | WO2002100394A1 Oral pharmaceutical composition containing a statin derivative |
| 12/19/2002 | WO2002100392A1 Orally administered dosage forms of gaba analog prodrugs having reduced toxicity |
| 12/19/2002 | WO2002100385A1 Crude drug patch |
| 12/19/2002 | WO2002100382A2 Controlled release dosage forms using acrylic polymer, and process for making the same |
| 12/19/2002 | WO2002100377A1 PHARMACEUTICAL FORMULATION FOR THE EFFICIENT ADMINISTRATION OF APOMORPHINE, 6aR-(-)-N-PROPYL-NORAPOMORPHINE AND THEIR DERIVATIVES AND PRO-DRUGS THEREOF |
| 12/19/2002 | WO2002100353A2 Cd10-activated prodrug compounds |
| 12/19/2002 | WO2002100348A2 Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
| 12/19/2002 | WO2002100347A2 Prodrugs of gaba analogs, compositions and uses thereof |
| 12/19/2002 | WO2002100344A2 Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| 12/19/2002 | WO2002100343A2 N-terminally truncated galectin-3 and antibodies for treating cancer |
| 12/19/2002 | WO2002100338A2 Compound and composition for delivering active agents |
| 12/19/2002 | WO2002100336A2 Tissue-specific endothelial membrane proteins |
| 12/19/2002 | WO2002100319A2 Method for cleaning hard gelatine capsules |
| 12/19/2002 | WO2002100309A1 Quinolone carboxylic acid compositions and related methods of treatment |
| 12/19/2002 | WO2002100269A1 Compositions and methods for magnetically labeling cells |
| 12/19/2002 | WO2002100192A1 Taste modifiers comprising a chlorogenic acid |
| 12/19/2002 | WO2002100172A1 Administration of agents via the pept-2 transporter |
| 12/19/2002 | WO2002080981A3 Polynucleotide binding complexes comprising sterols and saponins |
| 12/19/2002 | WO2002080754A3 Methods for using annexin for detecting cell death in vivo and treating associated conditions |
| 12/19/2002 | WO2002067894A3 Fast dissolving tablets of cyclooxygenase-2 enzyme inhibitors |
| 12/19/2002 | WO2002066012A3 Amphoteric liposomes and the use thereof |
| 12/19/2002 | WO2002065981A3 Chemotherapeutic composition using calcium phosphate paste |
| 12/19/2002 | WO2002058705A3 Degradation-resistant glucocorticosteroid formulations |
| 12/19/2002 | WO2002056878A3 Pharmaceutical composition having reduced tendency for drug crystallization |
| 12/19/2002 | WO2002044360A3 Modified arginine deiminase |
| 12/19/2002 | WO2002005836A3 Stimulation of bone growth with thrombin peptide derivatives |
| 12/19/2002 | WO2001087301A9 Methods for treatment of inflammatory diseases |
| 12/19/2002 | WO2001068679A9 Peptides targeting specifically tumor-derived endothelial cells |
| 12/19/2002 | US20020194638 Vector for genetically modifying non-human animals |
| 12/19/2002 | US20020193875 Agent promoting the formation of skin basement membrane, agents promoting the formation of artificial skin and process for producing artificial skin |
| 12/19/2002 | US20020193572 Generation of glycosylated antibody; obtain cell, incubate with vector expressing preferential antibody, transfected with a vector, propagate, express vector, recover antibody |
| 12/19/2002 | US20020193570 Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
| 12/19/2002 | US20020193544 Water-soluble or water-swellable crosslinked copolymers |
| 12/19/2002 | US20020193445 Controlled release for fast peak plasma concentration of the active metabolite desglymidodrine; treating orthostaic hypotension and/or urinary incontinence |
| 12/19/2002 | US20020193438 Aripiprazole oral solution |
| 12/19/2002 | US20020193409 Prodrugs of anticancer agents employing substituted aromatic acids |
| 12/19/2002 | US20020193397 Nasal delivery of apomorphine |
| 12/19/2002 | US20020193391 Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects |
| 12/19/2002 | US20020193350 Contacting a sample containing sperm with a solution comprising a polysaccharide containing arabinose, galactose and/or hexuronic acid (PCAGH) to form a mixture, wherein the PCAGH is not arabinogalactan; separating sperm from the sample |